Patient-Friendly Explanation
Rimonabant was one of the first weight-loss medicines to target the brain’s appetite and reward system. It helped people lose weight but was withdrawn because it caused depression and other mental health side effects in some users. Its story shows why new weight-loss medicines are watched closely for effects on mood.
Clinical Definition
Rimonabant was the first selective cannabinoid CB1 receptor antagonist approved for weight management, reducing appetite and adiposity via blockade of the endocannabinoid system. It was withdrawn in 2008 after meta-analyses linked it to an elevated risk of psychiatric adverse events, including depression, anxiety, and suicidal ideation.
Why It Matters
Rimonabant’s withdrawal underscores why weight-loss medications require careful safety evaluation. NuLifeCare Singapore provides medically supervised weight management with close monitoring for both physical and mental wellbeing.